サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1550381

自己血管内シャントデバイス市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、最終用途別、地域別、競合、2019-2029F

Arteriovenous Fistula Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End-use, By Region, and Competition, 2019-2029F

出版日
ページ情報
英文 187 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

自己血管内シャントデバイス市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、最終用途別、地域別、競合、2019-2029F
出版日: 2024年09月06日
発行: TechSci Research
ページ情報: 英文 187 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

自己血管内シャント（AVF）デバイスの世界市場の市場規模は、2023年に3億12万米ドルで、2029年までの予測期間のCAGRは7.25%で目覚ましい成長が予測されています。

世界の自己血管内シャントデバイス市場は、慢性腎臓病（CKD）の有病率の上昇と効果的な血液透析治療へのニーズの高まりにより、近年著しい成長と進化を遂げています。自己血管内シャントデバイスは、特に末期腎不全（ESRD）患者において、血液透析のための効率的で安全なバスキュラーアクセスを確保する上で極めて重要な役割を果たしています。市場の成長は、いくつかの重要な要因に後押しされています。第一に、世界の高齢化によりCKDとESRDの罹患率が増加し、血液透析の需要が高まっています。動静脈瘻（AV瘻）装置は、血液透析治療のための信頼性の高いアクセスを提供するために、動脈と静脈（通常は腕）の間に直接接続を作るために使用される医療介入です。血液透析は、腎臓が正常に機能しなくなった場合に、血液から老廃物や余分な水分をろ過するために用いられる医療処置です。AV瘻は、定期的な血液透析治療を必要とする末期腎不全患者（ESRD）によく使用されます。AV瘻は、通常、前腕または上腕にある動脈と静脈を外科的につなぎ合わせて作られます。この接続により、静脈への血流が増加し、血液透析セッション中に何度も針を挿入しても静脈が太くなり、耐久性が増します。また、血流が増加することで、血液中の老廃物をより効率的に除去することができます。自己血管内シャントデバイスは、長期的なバスキュラーアクセスのための優れた選択肢を提供し、感染リスクを最小限に抑え、透析効率を最適化することで、その普及にさらに拍車をかけています。

市場概要
予測期間 2025-2029
市場規模：2023年 3億12万米ドル
市場規模：2029年 4億4,450万米ドル
CAGR：2024年～2029年 7.25%
急成長セグメント AVF作成デバイス
最大市場 北米

医療技術の進歩は、自己血管内シャントデバイスの技術革新にも拍車をかけています。メーカー各社は、より生体適合性が高く、耐久性に優れ、合併症を起こしにくいデバイスを開発しています。これらの技術革新は、患者の快適性を高め、介入頻度を減らし、瘻孔の寿命を延ばすことで、患者の転帰全体を改善することを目指しています。地域別では、北米、欧州、アジア太平洋、その他の地域が市場の成長に寄与しています。インドや中国などのアジア太平洋地域の新興経済諸国では、医療インフラや先進医療へのアクセスが顕著に増加しており、自己血管内シャントデバイスの需要を牽引しています。しかし、市場には課題も残っています。瘻孔の形成には複雑な外科手術が必要で、熟練した医療専門家が要求され、瘻孔の成熟期間が複雑さに拍車をかけています。動静脈グラフトや中心静脈カテーテルなどの代替バスキュラーアクセス法も引き続き利用されており、自己血管内シャントデバイス市場に競合をもたらしています。世界の自己血管内シャントデバイス市場は、CKDの有病率の上昇、医療技術の進歩、ヘルスケアインフラの拡大により、力強い成長を遂げています。市場が進化を続ける中、これらの機器の性能、耐久性、患者への利便性をさらに高めることを目的とした研究開発が重視されるようになってきています。血液透析を受ける患者の生活の質を向上させることにますます焦点が当てられているため、自己血管内シャントデバイス市場は、現代の腎臓内科医療にとって重要な要素であり続けると思われます。

主な市場促進要因

慢性腎臓病（CKD）の有病率の上昇

血液透析治療のニーズの高まり

ヘルスケア支出の増加

主な市場課題

複雑な手術手技

瘻孔の成熟時間

主な市場動向

遠隔医療と遠隔モニタリング

調査と臨床試験

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の自己血管内シャントデバイス（AVF）市場見通し

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別（AVF作成デバイス、AVF監視デバイス、AVFメンテナンスデバイス）
    • 用途別（病院、心臓センター、その他）
    • 地域別
    • 企業別（2023）
  • 市場マップ

第6章 北米の自己血管内シャントデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 最終用途別
    • 国別
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の自己血管内シャントデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 最終用途別
    • 国別
  • 欧州：国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の自己血管内シャントデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 最終用途別
    • 国別
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米の自己血管内シャントデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 最終用途別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの自己血管内シャントデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 最終用途別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品開発
  • 最近の動向

第13章 競合情勢

  • Medtronic plc
  • Becton, Dickinson and Company
  • Teleflex Incorporated
  • Fresenius Medical Care AG & Co. KGaA.
  • B. Braun SE
  • Poly Medicure Ltd.
  • NxStage Medical, Inc.
  • Laminate Medical Technologies Ltd.

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 23877

Global Arteriovenous Fistula Devices Market (AVF) was valued at USD 300.12 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2029. The global arteriovenous fistula devices market has experienced significant growth and evolution in recent years, driven by the rising prevalence of chronic kidney diseases (CKD) and the increasing need for effective hemodialysis treatments. Arteriovenous fistula devices play a pivotal role in ensuring efficient and safe vascular access for hemodialysis, particularly in patients with end-stage renal disease (ESRD). The market's growth is propelled by several key factors. First, the growing aging population worldwide has contributed to an increased incidence of CKD and ESRD, thereby augmenting the demand for hemodialysis procedures. An arteriovenous fistula (AV fistula) device is a medical intervention used to create a direct connection between an artery and a vein, typically in the arm, to provide reliable access for hemodialysis treatment. Hemodialysis is a medical procedure used to filter waste and excess fluids from the blood when a person's kidneys are no longer functioning properly. The AV fistula device is commonly used in patients with end-stage renal disease (ESRD) who require regular hemodialysis treatments. The AV fistula is surgically created by connecting an artery and a vein together, usually in the forearm or upper arm. This connection causes increased blood flow into the vein, making it larger and more durable for repeated needle insertions during hemodialysis sessions. The increased blood flow also helps remove waste products from the blood more efficiently. Arteriovenous fistula devices offer a superior option for long-term vascular access, minimizing infection risks and optimizing dialysis efficiency, which has further fueled their adoption.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 300.12 Million
Market Size 2029USD 444.50 Million
CAGR 2024-20297.25%
Fastest Growing SegmentAVF Creation Devices
Largest MarketNorth America

The advancements in medical technology have also spurred innovation in arteriovenous fistula devices. Manufacturers are developing devices that are more biocompatible, durable, and less prone to complications. These innovations aim to enhance patient comfort, reduce intervention frequency, and prolong the lifespan of the fistula, thereby improving overall patient outcomes. Geographically, the market exhibits a widespread presence, with North America, Europe, Asia Pacific, and other regions all contributing to its growth. Developing economies in Asia Pacific, such as India and China, have seen a notable increase in healthcare infrastructure and access to advanced medical treatments, driving the demand for arteriovenous fistula devices. However, challenges remain within the market. The intricate surgical procedure required for fistula creation demands skilled healthcare professionals, and the maturation period of the fistula adds to the complexity. The alternative vascular access methods, such as arteriovenous grafts and central venous catheters, continue to be utilized, presenting competition to the arteriovenous fistula devices market. The global arteriovenous fistula devices market is witnessing robust growth due to the escalating prevalence of CKD, advancements in medical technology, and expanding healthcare infrastructures. As the market continues to evolve, there is a growing emphasis on research and development, aiming to further enhance the performance, durability, and patient-friendliness of these devices. With an ever-increasing focus on improving the quality of life for patients undergoing hemodialysis, the arteriovenous fistula devices market is likely to remain a crucial component of modern nephrology care.

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD)

The rising prevalence of chronic kidney disease (CKD) has emerged as a significant driver shaping the global arteriovenous fistula devices market. CKD refers to the progressive and irreversible deterioration of kidney function over time, and it represents a growing public health concern worldwide. This escalating prevalence has profound implications for the demand and adoption of arteriovenous fistula devices. Several factors contribute to the increasing prevalence of CKD. Demographic shifts, including an aging global population, play a pivotal role. As individuals age, their kidneys naturally undergo changes, and older adults are more susceptible to kidney dysfunction. This demographic trend has led to a higher incidence of CKD cases, consequently driving the demand for renal replacement therapies such as hemodialysis. Secondly, the global surge in non-communicable diseases, particularly diabetes and hypertension, has amplified CKD rates. Both conditions are leading causes of kidney damage, with diabetes causing diabetic nephropathy and hypertension leading to hypertensive nephropathy. These comorbidities result in a higher likelihood of kidney function decline, necessitating renal replacement therapies like hemodialysis, which often requires arteriovenous fistula devices. The lifestyle factors, including unhealthy diets and sedentary behavior, contribute to the rise in CKD cases. Poor dietary choices and inadequate physical activity can contribute to obesity, diabetes, and hypertension, all of which increase the risk of kidney damage and CKD development. The increasing global awareness of CKD and its impact on public health has led to improved screening and early detection efforts. As more cases of CKD are identified in their early stages, the need for effective and reliable vascular access for hemodialysis, such as arteriovenous fistula devices, becomes even more pronounced.

Growing Need for Hemodialysis Treatment

The growing need for hemodialysis treatment has become a significant driving force in shaping the global arteriovenous fistula devices market. Hemodialysis is a life-sustaining medical procedure used to filter waste products and excess fluids from the blood when the kidneys fail to adequately perform these functions. This escalating demand for hemodialysis has direct implications for the adoption and utilization of arteriovenous fistula devices. One of the primary contributors to the increased need for hemodialysis is the rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) on a global scale. As CKD progresses to its advanced stages, kidney function declines to the point where dialysis becomes essential for maintaining the body's internal balance. This has led to a growing population of patients who require regular hemodialysis sessions for survival. The changing disease patterns and lifestyle factors, such as the global surge in diabetes and hypertension, have contributed to the increase in ESRD cases. These conditions are known to accelerate kidney damage, leading to a higher likelihood of kidney function deterioration and the subsequent need for hemodialysis treatment. The availability of hemodialysis treatment has also expanded due to advances in medical infrastructure and technology. Healthcare systems in many countries have developed or improved their dialysis facilities, making this life-sustaining therapy more accessible to a larger number of patients. This, in turn, has bolstered the demand for arteriovenous fistula devices, which provide a durable and effective means of vascular access for hemodialysis. As the global population ages and the burden of chronic diseases continues to rise, the need for hemodialysis treatment is expected to further intensify. The arteriovenous fistula device market is poised to benefit from this trend as these devices offer a reliable and long-lasting solution for creating the necessary access points for hemodialysis procedures. Ensuring optimal vascular access becomes paramount to enhance patient outcomes and minimize complications, making arteriovenous fistula devices a critical component in meeting the growing need for hemodialysis treatment worldwide.

Increasing Healthcare Expenditure

The increasing healthcare expenditure across the globe has significant implications for the growth and development of the global arteriovenous fistula devices market. Healthcare expenditure encompasses the financial resources allocated to medical services, treatments, and technologies, and its upward trajectory has a direct impact on the demand for and utilization of arteriovenous fistula devices. As economies expand and healthcare systems evolve, there is a growing recognition of the importance of addressing chronic diseases and providing advanced medical interventions. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the conditions that require substantial healthcare resources, including renal replacement therapies like hemodialysis. Arteriovenous fistula devices play a pivotal role in hemodialysis, serving as a reliable and durable means of vascular access. The increasing healthcare expenditure enables healthcare systems to invest in the infrastructure, facilities, and medical devices necessary for delivering quality hemodialysis care, including the adoption of arteriovenous fistula devices. The availability of financial resources enables research and development initiatives aimed at advancing medical technologies, including arteriovenous fistula devices. Manufacturers can invest in designing and producing more innovative, patient-friendly, and efficient devices that align with evolving healthcare needs and quality standards. This continuous innovation not only enhances patient comfort and safety but also contributes to the growth of the arteriovenous fistula devices market.

Key Market Challenges

Complex Surgical Procedures

Complex surgical procedures in the context of the global arteriovenous fistula devices market refer to the intricate and skill-intensive techniques involved in creating and managing arteriovenous fistulas (AVFs) for hemodialysis access. AVFs are surgically constructed connections between an artery and a vein, usually in the arm, allowing for increased blood flow and a reliable access point for hemodialysis treatment. While AVFs offer numerous benefits, the complexity of the surgical procedures can present challenges and considerations within the market. The creation of an AVF involves delicate surgical techniques that demand a high level of expertise from medical professionals, typically vascular surgeons. The surgeon must identify suitable arteries and veins, make precise incisions, and skillfully connect them to establish a functional fistula. Proper placement, appropriate vessel size, and ensuring adequate blood flow are crucial aspects of the procedure. The surgery requires precision and a deep understanding of vascular anatomy to minimize complications and optimize the chances of successful maturation. The complexity of AVF procedures can impact the broader arteriovenous fistula devices market in several ways. Healthcare providers need to ensure that their medical staff is adequately trained and experienced in performing AVF surgeries. Manufacturers of AVF devices may focus on designing tools and technologies that simplify the surgical process, reduce complications, and improve patient outcomes. The patient education about the importance of optimal vascular access and the complexities involved can enhance patient cooperation and understanding.

Fistula Maturation Time

Fistula maturation time is a critical factor in the context of the global arteriovenous fistula devices market, referring to the period required for an arteriovenous fistula (AVF) to fully develop and become suitable for use in hemodialysis. Hemodialysis is a life-saving medical procedure that involves removing waste products and excess fluids from the blood when the kidneys are unable to perform this function adequately. AVFs are surgically created connections between an artery and a vein, enabling efficient blood flow and providing a reliable access point for hemodialysis. The maturation of an AVF is a complex physiological process. After the surgical creation of the AVF, the vein gradually enlarges and strengthens, adapting to the increased blood flow from the connected artery. This maturation process involves the remodeling of blood vessels, the growth of new vessels (angiogenesis), and changes in vessel wall characteristics. These changes are necessary to ensure the vein can withstand repeated needle insertions during hemodialysis and provide the necessary blood flow rates for effective treatment. The time required for an AVF to mature can vary widely among individuals. On average, it may take several weeks to a few months for an AVF to reach its optimal state. However, some AVFs may mature more quickly, while others might take longer due to factors such as the patient's overall health, vascular condition, and the specific anatomical characteristics of the AVF. For the global arteriovenous fistula devices market, understanding and addressing fistula maturation time are crucial. Healthcare providers, manufacturers, and policymakers must work together to develop strategies that expedite and optimize AVF maturation. This can involve advancements in surgical techniques, post-operative care protocols, and patient education to ensure that patients receive timely and effective hemodialysis through mature AVFs. By reducing maturation times and improving the success rate of AVFs, the market can contribute to enhancing patient outcomes, reducing healthcare costs, and improving the overall quality of care for individuals with kidney disease.

Key Market Trends

Telehealth and Remote Monitoring

Telehealth and remote monitoring are innovative approaches that have been increasingly integrated into the global arteriovenous fistula devices market, transforming the way healthcare providers manage and monitor patients with arteriovenous fistulas (AVFs) for hemodialysis access. These technologies leverage digital communication to facilitate medical consultations, follow-ups, and real-time monitoring without the need for in-person visits. Telehealth involves the use of telecommunications technology to provide healthcare services and consultations remotely. In the context of the arteriovenous fistula devices market, telehealth enables healthcare professionals to connect with patients virtually, discuss their AVF progress, address concerns, and provide guidance. This approach is particularly valuable during the critical phase of AVF maturation when patients may have questions or require support. Remote monitoring extends telehealth by enabling continuous or periodic tracking of AVF-related parameters. Specialized sensors or devices can be used to collect data on blood flow, pressure, and other relevant metrics. This data is transmitted to healthcare providers for analysis, allowing them to monitor the AVF's function and detect any abnormalities or complications in real time. Remote monitoring enhances patient safety and allows for timely intervention if issues arise. Patients can receive medical guidance and support from the comfort of their homes, reducing the need for frequent clinic visits and long travel times. This is especially advantageous for patients living in remote or underserved areas. Remote monitoring enables healthcare providers to detect early signs of AVF complications, such as stenosis or thrombosis, and intervene promptly. This can prevent serious issues and potentially reduce the need for hospitalizations. Telehealth and remote monitoring empower patients to actively participate in their AVF management. Patients can learn about AVF care, track their progress, and communicate with healthcare professionals, leading to better self-management and adherence. By minimizing unnecessary in-person visits and hospitalizations, telehealth and remote monitoring have the potential to reduce healthcare costs for both patients and providers. Remote monitoring generates valuable data that healthcare providers can analyze to make informed decisions about AVF management strategies. This data-driven approach enhances the quality of care. Early detection and intervention through remote monitoring can contribute to better AVF maturation rates, fewer complications, and improved patient outcomes.

Therefore, the telehealth and remote monitoring are transformative tools in the global arteriovenous fistula devices market. By enhancing patient engagement, enabling timely interventions, and providing efficient healthcare delivery, these technologies contribute to optimizing AVF management and improving the overall quality of care for individuals undergoing hemodialysis.

Research and Clinical Trials

Research and clinical trials play a vital role in advancing the global arteriovenous fistula devices market by fostering innovation, improving patient outcomes, and enhancing the understanding of arteriovenous fistula (AVF) creation, maturation, and management. These initiatives involve systematic investigations conducted by researchers and medical professionals to explore new techniques, technologies, and approaches to optimize AVF-related procedures. Research in the arteriovenous fistula devices market encompasses a wide range of studies, including basic laboratory research, translational studies, and clinical investigations. Researchers aim to deepen their understanding of vascular physiology, AVF maturation mechanisms, and factors that influence the success or complications of AVFs. By gaining insights into these aspects, researchers can develop strategies to expedite maturation, reduce complications, and improve overall AVF functionality. Clinical trials, a subset of research, involve human participants and are conducted to evaluate the safety, efficacy, and feasibility of new interventions or medical devices. In the context of the arteriovenous fistula devices market, clinical trials might focus on testing novel device designs, surgical techniques, or post-operative care protocols. These trials provide valuable evidence-based data that can guide healthcare practices and influence the adoption of new technologies.

Segmental Insights

Type Insights

In 2023, the Arteriovenous Fistula Devices Market was dominated by the AVF creation devices segment. This is attributed de to its critical role in hemodialysis access creation. AVF creation devices facilitate the surgical formation of arteriovenous fistulas, the preferred vascular access for hemodialysis patients due to superior long-term outcomes and lower complication rates. As hemodialysis prevalence rises globally, driven by increasing incidences of renal diseases, the demand for AVF creation devices surges accordingly. The advancements in AVF creation techniques and devices, coupled with healthcare initiatives promoting AVF as the preferred access type, further bolster the dominance of this segment in the market and is predicted to continue expanding over the coming years. This is due rising prevalence of End-stage renal disease (ESRD) and the growing number of individuals requiring dialysis treatment have created a higher demand for AVF procedures. The significance of AVF creation devices lies in their essential role in addressing the increasing need for dialysis treatment. These devices facilitate efficient vascular access, thereby enhancing patient care and elevating the overall quality of life for individuals undergoing dialysis.

Regional Insights

North America accounted for the largest revenue share in 2023. This is ascribed due to advancements in technology, low cost of services, and availability of skilled workforce at a lower cost than developed economies and are anticipated to propel regional market growth. Increasing regulatory focus on quality control for manufacturing is one of the key factors expected to drive the growth over the forecast period. North America has a significant burden of kidney disease, and AVF devices play a crucial role in providing vascular access for hemodialysis.

Key Market Players

Medtronic PLC

Becton, Dickinson and Company

Teleflex Incorporated

Fresenius Medical Care AG & Co. KGaA.

B. Braun SE

Poly Medicure Ltd.

NxStage Medical, Inc.

Laminate Medical Technologies Ltd.

Report Scope:

In this report, the Global Arteriovenous Fistula Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Arteriovenous Fistula Devices Market, By Type:

    AVF Creation Devices
    • Surgical Instruments
    • Vascular Grafts
    • Angioplasty Balloons
    • Others
    AVF Monitoring Devices
    • Doppler Ultrasound
    • Pressure Monitoring Systems
    • Others
    AVF Maintenance Devices
    • Central Venous Catheters
    • Stents
    • Others

Arteriovenous Fistula Devices Market, By End-Use:

    Hospitals Cardiac Centers Others

Arteriovenous Fistula Devices Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Arteriovenous Fistula Devices Market.

Available Customizations:

Global Arteriovenous Fistula Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Arteriovenous Fistula Devices (AVF) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (AVF Creation Devices, AVF Monitoring Devices, AVF Maintenance Devices)
      • 5.2.1.1. By AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons, Others)
      • 5.2.1.2. By AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, Others)
      • 5.2.1.3. By AVF Maintenance Devices (Central Venous Catheters, Stents, Others)
    • 5.2.2. By End-use (Hospitals, Cardiac Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2023)
  • 5.3. Market Map

6. North America Arteriovenous Fistula Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Arteriovenous Fistula Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Arteriovenous Fistula Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Arteriovenous Fistula Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-use

7. Europe Arteriovenous Fistula Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Arteriovenous Fistula Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Arteriovenous Fistula Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Arteriovenous Fistula Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Arteriovenous Fistula Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Arteriovenous Fistula Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-use

8. Asia-Pacific Arteriovenous Fistula Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Arteriovenous Fistula Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-use
    • 8.3.2. Japan Arteriovenous Fistula Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-use
    • 8.3.3. India Arteriovenous Fistula Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Arteriovenous Fistula Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Arteriovenous Fistula Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-use

9. South America Arteriovenous Fistula Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Arteriovenous Fistula Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-use
    • 9.3.2. Argentina Arteriovenous Fistula Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-use
    • 9.3.3. Colombia Arteriovenous Fistula Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-use

10. Middle East and Africa Arteriovenous Fistula Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Arteriovenous Fistula Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-use
    • 10.3.2. Saudi Arabia Arteriovenous Fistula Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-use
    • 10.3.3. UAE Arteriovenous Fistula Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Competitive Landscape

  • 13.1. Medtronic plc
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. Becton, Dickinson and Company
  • 13.3. Teleflex Incorporated
  • 13.4. Fresenius Medical Care AG & Co. KGaA.
  • 13.5. B. Braun SE
  • 13.6. Poly Medicure Ltd.
  • 13.7. NxStage Medical, Inc.
  • 13.8. Laminate Medical Technologies Ltd.

14. Strategic Recommendations

15. About Us & Discalimer